Oracle
has announced plans to acquire
Relsys, a
firm that provides drug safety and risk management solutions to the health
sciences industry.
Terms of the deal have not been disclosed, but Oracle said that it will add
Relsys to its Health Sciences global business unit.
The database vendor claimed in a report that the combination of expertise
will deliver the "only suite of software applications that supports end-to-end
drug safety processes across clinical development, post-market surveillance and
patient care".
"The health sciences industry is increasing investments in software that
provides greater transparency into drug safety, and helps improve the overall
safety of therapies," said Neil de Crescenzo, Oracle Health Sciences senior vice
president and general manager.
"With the addition of Relsys, Oracle is uniquely positioned to help our
customers improve drug safety by delivering a comprehensive software solution
that enables our vision of integrated safety and risk management supported by
advanced analytics."
Do you agree?
Have your say on this article